Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 West | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

West

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

West Pharmaceutical Services 2Q08

2Q Revenues: $279.3 million (+6%)

2Q Earnings: $28.7 million (+8%)

YTD Revenues: $550.0 million (+6%)

YTD Earnings: $55.0 million (+4%)

Comments: Revenues from the Pharmaceutical Systems unit were up 12% to $212.6 million, but were adversely affected by the slowdown in ESA drugs, including Amgen’s Epogen. In addition, two-thirds of that unit’s revenue growth derived from the weak dollar. Sales at the Tech Group unit dropped $8.1 million to $69.6 million, due to the loss of the Exubera inhaler ($10.2 million in sales) and packaging for an OTC diet product ($4.2 million). During the quarter, the company received final payment from Nektar Therapeutics to compensate for the cancellation of Exubera.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters